RHYTHM PHARMACEUTICALS, INC. cotiza a 90.78 USD y tiene una capitalización bursátil de $6.3B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.73 | $-0.83 | $-0.73 |
| Estimado | $-0.75 | $-0.83 | $-0.86 | $-0.78 |
| Sorpresa | — | +12.0% | +3.5% | +6.4% |
| Métrica | RYTM | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 89.7% | 57.0% | +32.7% |
| Operating Margin | -101.2% | -38.6% | -62.6% |
| Net Margin | -103.6% | -33.6% | -70.0% |
| FCF Margin | -61.5% | -13.9% | -47.6% |
| ROE | -141.3% | -40.4% | -100.9% |
| ROA | -40.9% | -32.0% | -8.9% |
| Current Ratio | 4.41 | 2.84 | +1.57 |
| Debt / Equity | 0.73 | 0.28 | +0.45 |